多柔比星、长春碱、达卡巴嗪联合来那度胺治疗老年霍奇金淋巴瘤患者:德国霍奇金研究组(GHSG)I期试验最终结果
约30%的霍奇金淋巴瘤(HL)患者年龄≥60岁。本I期试验将ABVD方案中的博来霉素替换为来那度胺,纳入25例中位年龄68岁的早期不良或晚期HL患者,采用过量控制递增法给予AVD联合来那度胺4-8周期。推荐的II期剂量为20 mg,总缓解率80%,3年无进展生存率69.7%,总生存率83.8%。
要点
- 推荐的II期剂量为来那度胺20 mg,剂量限制性毒性见于10/24可评估患者。
- 所有患者总缓解率80%(20/25),来那度胺≥20 mg组为86%(19/22)。
- 3年无进展生存率69.7%,总生存率83.8%,来那度胺≥20 mg组所有22例发生≥3级毒性。
核心结论
- AVD联合来那度胺20 mg在老年霍奇金淋巴瘤患者中可行且高效。
研究设计与样本
- 德国霍奇金研究组(GHSG)I期试验,纳入25例年龄≥60岁的早期不良或晚期霍奇金淋巴瘤患者,中位年龄68岁,68%为晚期。
- 患者体能状态(ECOG)≤2,老年累积疾病评定量表评分0-7,接受4-8周期AVD联合来那度胺过量控制递增治疗。
主要发现
- 剂量限制性毒性见于10/24可评估患者,均接受≥20 mg来那度胺。
- 中位相对剂量强度为97%(四分位距49-104%)。
- 来那度胺≥20 mg组所有22例发生≥3级毒性,无治疗相关死亡。
- 所有患者总缓解率80%(20/25),来那度胺≥20 mg组为86%(19/22)。
- 3年无进展生存率估计为69.7%(95% CI:50.3-89.1%),总生存率为83.8%(95% CI:69.3-98.4%)。
关键数值与推荐
- 推荐的II期剂量(RPTD)为来那度胺20 mg。
- 剂量限制性毒性包括≥2级血栓栓塞、严重血液学毒性、中性粒细胞减少性发热和治疗延迟延长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
About 30% of all Hodgkin lymphoma (HL) patients are ≥60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL, we replaced bleomycin in ABVD with lenalidomide in this phase-I trial. Patients aged ≥60 years with early-unfavourable- or advanced-stage HL (Eastern Cooperative Oncology Group performance status ≤2, Cumulative Illness Rating Scale for Geriatrics score 0-7) received 4-8 cycles of AVD (doxorubicin, vinblastine, dacarbazine) and lenalidomide in escalation with overdose control. Dose-limiting toxicities (DLTs) included thromboembolism ≥grade 2, severe haematological toxicity, neutropenic fever and prolonged therapy delay. Twenty-five patients with a median age of 68 years were included, 68% had advanced-stage HL. A pre-defined stopping criterion for dose escalation after DLT evaluation of 20/24 patients suggested a recommended phase II dose (RPTD) of 20 mg. DLTs occurred in 10/24 evaluable patients, all treated with ≥20 mg, however, median relative dose intensity was 97% (interquartile range 49-104%). Grade 3 or higher toxicities occurred in all 22 patients at ≥20 mg lenalidomide but no treatment-related deaths occurred. Overall response rate was 80% for all patients (20/25) and 86% (19/22) at ≥20 mg lenalidomide. Three-year estimates for progression-free survival and OS were 69·7% (95% CI: 50·3-89·1%) and 83·8% (95%-CI: 69·3-98·4%), respectively. In conclusion, AVD with lenalidomide 20 mg is feasible and highly effective in older HL patients.
引用
- Böll B, Plütschow A, Bürkle C, et al. Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br J Haematol. 2018. PMID: 30592027. doi:10.1111/bjh.15741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。